What is palmitoylethanolamide? A complete technical primer
Chemistry, history, mechanism, evidence, safety and supply — the whole molecule in one place.
Read the article
Knowledge hub
Everything we know about palmitoylethanolamide, written down.
Technical articles for formulators, regulatory teams, buyers and clinicians. Cited, dated, and revised when the literature moves. Nothing here is a sales page in disguise.
Micronized vs ultra-micronized PEA: what the particle-size data actually shows
The evidence for micronising, the point of diminishing returns, and how to specify particle size properly.
Read the articlePEA dosage: what doses the clinical trials used
Dose by indication, titration patterns, onset timelines, and why a 30-day trial under-reads the ingredient.
Read the articlePEA vs CBD: two endocannabinoid-adjacent molecules that are not the same thing
Mechanism, evidence, safety and regulatory status compared — without the marketing.
Read the articlePEA for neuropathic and nerve compression pain
The strongest part of the evidence base, the negative trial that complicates it, and what it means for positioning.
Read the articlePEA for dogs and cats: the companion-animal category
Controlled trial data in 50 dogs and 50 cats, dosing, formats, and why this category is under-supplied.
Read the articleAlso useful
Reference pages across the site
Mechanism of action
PPAR-α, the ALIA hypothesis, the entourage effect, and what is still disputed.
Clinical evidence library
The full trial table with meta-analyses, RCTs and the negative results.
Grades & specification
Particle-size targets, release limits and analytical methods.
Regulatory status
FSSAI, TGA, Health Canada, EU, US — with the gaps marked as gaps.
Next step
Request a specification, a sample, or a quotation
Send us your target dose, format and volume. Our technical team replies with a full documentation pack — specification, method summary, batch CoA and regulatory dossier — within one business day.